Cost-Effectiveness Analysis (CEA) of Linezolid Versus Vancomycin in the Treatment of Nosocomial Pneumonia Caused by Methicillin-Resistant Staphylococcus Aureus (MRSA-NP) Based on a Phase IV Clinical Trial- Results from Four Major Cities in ...

Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.209
https://www.valueinhealthjournal.com/article/S1098-3015(13)02114-1/fulltext
Title : Cost-Effectiveness Analysis (CEA) of Linezolid Versus Vancomycin in the Treatment of Nosocomial Pneumonia Caused by Methicillin-Resistant Staphylococcus Aureus (MRSA-NP) Based on a Phase IV Clinical Trial- Results from Four Major Cities in ...
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02114-1&doi=10.1016/j.jval.2013.08.209
First page : A358
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 196
Categories :
Tags :
Regions :
ViH Article Tags :